Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Innovus Pharma to Present at the Sachs BioCapital USA Forum at the New York Academy of Sciences

Innovus Pharmaceuticals,Inc.
Posted on: 09 Mar 18

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that Dr. Bassam Damaj, President and Chief Executive Officer and Rauly Gutierrez, Vice President, Finance, will present at the Sachs BioCapital USA Forum in New York City on Wednesday, March 21, 2018. They will present an update on the Company’s growing revenues, the launch of new products and other of the Company’s business plans.

Dr. Damaj and Mr. Gutierrez will also be meeting with members of the investment community and with potential business development partners during one-on-one meetings at the conference as well. The corporate presentation will be available for download on the Innovus Pharma web site (www.innovuspharma.com).

“We are honored to present at the New York Academy of Sciences and we look forward to updating the market on our growth and discussing new business development opportunities with potential Company partners,” said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.

About Conference Presentation time

Event: Sachs BioCapital USA Forum

Date: Wednesday, March 21, 2018

Time: 2:40 pm EST

Location: The Presenting Room, New York Academy of Sciences, 7 World Trade Center 250 Greenwich St., 40th Floor (D Elevator Bank)New York, New York 10007

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; and www.apeaz.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from its various products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005133/en/

Business Wire
www.businesswire.com

Last updated on: 09/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.